Trisenox and c-reactive protein increased Patient Reports February 13, 2012

Trisenox Side Effects Report #5536194-4
Trisenox side effect was reported by a Physician from JAPAN on Nov 20, 2007. Male patient, 88 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, c-reactive protein increased, electrocardiogram qt prolonged, fluid retention, gamma-glutamyltransferase increased, hepatic function abnormal. Trisenox dosage: 7.05 MG QD INTRAVENOUS DRIP. During the same period patient was treated with SULFAMETHOXAZOLE AND TRIMETHOPRIM, POLYMYXIN B SULPHATE. Patient recovered.

Trisenox Side Effects Report #5047197-0
Trisenox side effect was reported by a Physician from JAPAN on June 21, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, disseminated intravascular coagulation, haemoglobin decreased, hypokalaemia, malignant neoplasm progression, platelet count decreased, renal failure, respiratory failure. Trisenox dosage: 4.1 MG QD, INTRAVENOUS DRIP. During the same period patient was treated with FUROSEMIDE, MEXILETINE HYDROCHLORIDE, NIFEDIPINE, NIZATIDINE, INSULIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5022383-4
Trisenox side effect was reported by a Physician from JAPAN on May 30, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, hypokalaemia, platelet count decreased, white blood cell count decreased. Trisenox dosage: 4.1 MG QD INTRAVENOUS DRIP. During the same period patient was treated with FUROSEMIDE, MEXILETINE HYDROCHLORIDE, NIFEDIPINE, NIZATIDINE, INSULIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5029162-2
Trisenox side effect was reported by a Physician from JAPAN on May 31, 2006. Female patient, 84 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia, c-reactive protein increased, haemoglobin decreased, hypokalaemia, malignant neoplasm progression, platelet count decreased, white blood cell count decreased. Trisenox dosage: 4.1 MG QD INTRAVENOUS DRIP. During the same period patient was treated with FUROSEMIDE, MEXILETINE HYDROCHLORIDE, NIFEDIPINE, NIZATIDINE, INSULIN. Patient was hospitalized. Patient recovered.


Trisenox Side Effects Report #5081599-1
Trisenox side effect was reported by a Physician from JAPAN on July 27, 2006. Female patient, 77 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood lactate dehydrogenase increased, c-reactive protein increased, electrocardiogram qt prolonged, fibrin d dimer increased, gamma-glutamyltransferase increased, protein total decreased. Trisenox dosage: 9.315 MG QD INTRAVENOUS DRIP. Patient recovered.

Trisenox Side Effects Report #5361222-9
Trisenox side effect was reported by a Physician from JAPAN on June 04, 2007. Male patient, 73 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood pressure systolic decreased, bone marrow failure, c-reactive protein increased, haemoglobin decreased, neutrophil count decreased, platelet count decreased, pleural effusion, respiratory arrest, urine output decreased. Trisenox dosage: 9 MG QD INTRAVENOUS DRIP. During the same period patient was treated with CYTARABINE, METHOTREXATE, ARBEKACIN SULPHATE, ARBEKACIN SULPHATE, ARBEKACIN SULPHATE, PREDNISOLONE SUCCINATE, NAFAMOSTAT, LENOGRASTIM. Patient died on 05/06/2007.

Trisenox Side Effects Report #5391724-0
Trisenox side effect was reported by a Physician from JAPAN on July 10, 2007. Male patient, 73 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood pressure systolic decreased, bone marrow failure, c-reactive protein increased, pleural effusion, rash , respiratory arrest, resuscitation, urine output decreased. Trisenox dosage: 9 MG QD INTRAVENOUS DRIP. During the same period patient was treated with CYTARABINE, METHOTREXATE, ARBEKACIN SULPHATE, ARBEKACIN SULPHATE, ARBEKACIN SULPHATE, PREDNISOLONE SUCCINATE, NEFAMOSTAT, LENOGRASTIM. Patient died on 05/06/2007.

Trisenox Side Effects Report #5127287-4
Trisenox side effect was reported by a Physician from JAPAN on Sept 26, 2006. Female patient, 68 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, hypoalbuminaemia, hypoproteinaemia, white blood cell count decreased. Trisenox dosage: unknown. During the same period patient was treated with IMIDAPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE, ZOLPIDEM TARTRATE. Patient recovered.

Trisenox Side Effects Report #5127284-9
Trisenox side effect was reported by a Physician from JAPAN on Sept 26, 2006. Female patient, 61 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: aspartate aminotransferase increased, c-reactive protein increased, condition aggravated, electrocardiogram qt prolonged, hepatic function abnormal, rash , white blood cell count decreased. Trisenox dosage: 9.15 MG QD INTRAVENOUS DRIP. During the same period patient was treated with SULFAMETHOXAZOLE, FLUCONAZOLE. Patient recovered.


Trisenox Side Effects Report #5266132-3
Trisenox side effect was reported by a Physician from JAPAN on Feb 27, 2007. Female patient, 57 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased, c-reactive protein increased, condition aggravated, disseminated intravascular coagulation. Trisenox dosage: unknown. During the same period patient was treated with CYTARABINE, IDARUBICIN, DANAPAROID, CARBAZOCHROME SULFONATE, TRANEXAMIC ACID, MONOAMMONIUM GLYCYRRHIZINATE. Patient died on 12/31/2006.

Trisenox Side Effects Report #5087025-0
Trisenox side effect was reported by a Physician from JAPAN on Aug 09, 2006. Female patient, 57 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, c-reactive protein increased, headache , hepatic function abnormal, platelet count decreased, rash , white blood cell count decreased. Trisenox dosage: 7.77 MG QD INTRAVENOUS DRIP. Patient recovered.

Trisenox Side Effects Report #4678283-2
Trisenox side effect was reported by a Physician from on Dec 27, 2004. Male patient, 55 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood lactate dehydrogenase increased, body temperature increased, c-reactive protein increased, constipation , dyspnoea, hypoxia, pleural effusion. Trisenox dosage: 12.3 MG (12.3 MG, DAILY), INTRAVENOUS. During the same period patient was treated with CYTARABINE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5047199-4
Trisenox side effect was reported by a Physician from JAPAN on June 23, 2006. Male patient, 54 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, hyperglycaemia, pyrexia. Trisenox dosage: 12 MG QD INTRAVENOUS DRIP. During the same period patient was treated with PREDNISOLONE, METHYLPREDNISOLONE, DALTEPARIN, MICAFUNGIN, ACYCLOVIR, AMIKACIN SULPHATE, TAZOBACTAM PIPERACILLIN, CEFTAZIDIME. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5022419-0
Trisenox side effect was reported by a Consumer or non-health professional from JAPAN on May 25, 2006. Male patient, 54 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, hyperglycaemia. Trisenox dosage: 12 MG QD INTRAVENOUS DRIP. During the same period patient was treated with PREDNISOLONE, METHYLPREDNISOLONE, DALTEPARIN, MICAFUNGIN, ACYCLOVIR, AMIKACIN SULPHATE, TEZOBACTAM PIPERACILLIN, CEFTAZIDIME. Patient recovered.


Trisenox Side Effects Report #5301086-2
Trisenox side effect was reported by a Physician from JAPAN on Mar 26, 2007. Female patient, 37 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: accelerated idioventricular rhythm, alanine aminotransferase increased, alopecia, aspartate aminotransferase increased, c-reactive protein increased, electrocardiogram qt corrected interval prolonged, gamma-glutamyltransferase increased, leukocytosis, nausea . Trisenox dosage: 8.978 MG QD INTRAVENOUS DRIP. During the same period patient was treated with MEXILETINE HYDROCHLORIDE, GRANISETRN HYDROCHLORIDE. Patient recovered.

Trisenox Side Effects Report #5175210-9
Trisenox side effect was reported by a Physician from JAPAN on Nov 22, 2006. Female patient, 37 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: accelerated idioventricular rhythm, acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, alopecia, aspartate aminotransferase increased, blood lactate dehydrogenase increased, c-reactive protein increased, electrocardiogram qt corrected interval prolonged, gamma-glutamyltransferase increased. Trisenox dosage: 8.978 MG QD INTRAVENOUS DRIP. During the same period patient was treated with MEXILETINE HYDROCHLORIDE, GRANISETRON. Patient recovered.

Trisenox Side Effects Report #4801211-3
Trisenox side effect was reported by a Physician from JAPAN on Sept 26, 2005. Female patient, 36 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: bacterial infection , blood bilirubin increased, c-reactive protein increased, electrocardiogram qt corrected interval prolonged, electrocardiogram qt prolonged, jaundice , neutrophil count decreased, pyrexia, white blood cell count decreased. Trisenox dosage: 6.93 MG QD INTRAVENOUS DRIP. During the same period patient was treated with LACTOBACILLUS CASEI, LENOGRASTIM, CEFCAPENE PIVOXIL, GENTAMICIN, BUFEXAMAC. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5368842-6
Trisenox side effect was reported by a Physician from JAPAN on June 13, 2007. Female patient, 32 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, c-reactive protein increased, electrocardiogram qt corrected interval prolonged, electrocardiogram qt prolonged, hepatic function abnormal, hypocalcaemia, leukopenia. Trisenox dosage: 9.15 MG QD INTRAVENOUS DRIP. During the same period patient was treated with FEXOFENADINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, GEFARNATE, ETIZOLAM, ZOLPIDEM TARTRATE. Patient recovered.

Trisenox Side Effects Report #5397292-1
Trisenox side effect was reported by a Physician from JAPAN on July 05, 2007. Female patient, 32 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, c-reactive protein increased, electrocardiogram qt prolonged, hepatic function abnormal, hypocalcaemia, pancytopenia. Trisenox dosage: 9.15 MG QD INTRAVENOUS DRIP. During the same period patient was treated with FEXOFENADINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, GEFARNATE, ETIZOLAM, ZOLPIDEM TARTRATE. Patient recovered.


Trisenox Side Effects Report #5084862-3
Trisenox side effect was reported by a Physician from JAPAN on Aug 01, 2006. Male patient, 30 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, c-reactive protein increased, electrocardiogram qt prolonged, febrile neutropenia, white blood cell count decreased. Trisenox dosage: 8.43 MG QD INTRAVENOUS DRIP. During the same period patient was treated with IMIPENEM CILASTATIN, BIFIDOBACTERIUM, LOPERAMIDE HYDROCHLORIDE, CEFEPIME DIHYDROCHLORIDE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5580740-1
Trisenox side effect was reported by a Physician from JAPAN on Dec 06, 2007. Male patient, 28 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, c-reactive protein increased, electrocardiogram qt prolonged, gamma-glutamyltransferase increased, haemoglobin decreased, hepatic function abnormal, tonsillitis. Trisenox dosage: 12 MG QD INTRAVENOUS DRIP. During the same period patient was treated with DALTEPARIN, SULFAMETHOXAZOLE AND TRIMETHOPRIM, FLUCONAZOLE, OMEPRAZOLE, ROXATIDINE ACETATE, FAMOTIDINE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #4553545-8
Trisenox side effect was reported by a Health Professional from on Dec 27, 2004. Male patient was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: c-reactive protein increased, dyspnoea, pleural effusion. Trisenox dosage: 12 MG (12 MG, DAILY), INTRAVENOUS. During the same period patient was treated with CYTARABINE. Patient was hospitalized. Patient recovered.